Top

European Journal of Nutrition

Published in:

01-09-2020 | Folic Acid | Original Contribution

Folic acid prevents the progesterone-promoted proliferation and migration in breast cancer cell lines

Authors: Hui-Chen Wang, Yen-Nien Huo, Wen-Sen Lee

Published in: European Journal of Nutrition | Issue 6/2020

Abstract

Purpose

We previously demonstrated that progesterone (P4) interacted with folic acid (FA) and abolished the FA-reduced endothelial cell proliferation and migration. These findings led us to investigate whether FA can interfere with the P4-promoted breast cancer cell proliferation and migration.

Methods

We conducted MTT and wound healing assay to evaluate cell proliferation and migration, respectively. Western blot analysis and immunoprecipitation were performed to examine the protein expression and protein–protein interaction, respectively.

Results

We demonstrated that P4 promoted proliferation and migration of breast cancer cell lines (T47D, MCF-7, BT474, and BT483). However, co-treatment with P4 and FA together abolished these promotion effects. Treatment with P4 alone increased the formation of PR-cSrc complex and the phosphorylation of cSrc at tyrosine 416 (Tyr416). However, co-treatment with P4 and FA together increased the formations of cSrc-p140Cap, cSrc-Csk, and cSrc-p-Csk complex, and the phosphorylation of cSrc at tyrosine 527 (Tyr527). Co-treatment with P4 and FA together also abolished the activation of cSrc-mediated signaling pathways involved in the P4-promoted breast cancer cell proliferation and migration.

Conclusions

Co-treatment with FA and P4 together abolished the P4-promoted breast cancer cell proliferation and migration through decreasing the formation of PR-cSrc complex and increasing the formations of cSrc-p140Cap and cSrc-Csk complex, subsequently activating Csk, which in turn suppressed the phosphorylation of cSrc at Tyr416 and increased the phosphorylation of cSrc at Tyr527, hence inactivating the cSrc-mediated signaling pathways. The findings from this study might provide a new strategy for preventing the P4-promoted breast cancer progress.

MacMahon B, Cole BP, Brown J (1973) Etiology of human breast cancer: a review. J Natl Cancer Inst 50(1):21–42. https://doi.org/10.1093/jnci/50.1.21 CrossRefPubMed

Dao TL (1981) The role of ovarian steroid hormones in mammary carcinogenesis. In: Pike MC, Siiteri PK, Welsch CW (eds) Hormones and breast cancer. Banbury report no. 8. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 281–289

Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):7–35. https://doi.org/10.1093/oxfordjournals.epirev.a036102 CrossRef

Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616. https://doi.org/10.1093/jnci/94.8.606 CrossRefPubMed

Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427. https://doi.org/10.1016/S0140-6736(03)14065-2 CrossRefPubMed

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712. https://doi.org/10.1210/me.2006-0337 CrossRefPubMed

Travis RC, Key TJ (2003) Oestrogen exposure and breast cancer risk. Breast Cancer Res 5(5):239–247. https://doi.org/10.1001/jama.291.14.1701 CrossRefPubMedPubMedCentral

Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP (2007) The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21(2):359–375. https://doi.org/10.1210/me.2006-0337 CrossRefPubMed

Skildum A, Faivre E, Lange CA (2005) Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 19(2):327–339. https://doi.org/10.1210/me.2004-0306 CrossRefPubMed

10.

Saitoh M, Ohmichi M, Takahashi K, Kawagoe J, Ohta T, Doshida M, Takahashi T, Igarashi H, Mori-Abe A, Du B, Tsutsumi S, Kurachi H (2005) Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology 146(11):4917–4925. https://doi.org/10.1210/en.2004-1535 CrossRefPubMed

11.

Fu XD, Giretti MS, Baldacci C, Garibaldi S, Flamini M, Sanchez AM, Gadducci A, Genazzani AR, Simoncini T (2008) Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One 3(7):e2790. https://doi.org/10.1371/journal.pone.0002790 CrossRefPubMedPubMedCentral

12.

Wang HC, Lee WS (2016) Molecular mechanisms underlying progesterone-enhanced breast cancer cell migration. Sci Rep 6:31509. https://doi.org/10.1038/srep31509 CrossRefPubMedPubMedCentral

13.

Wang HC, Lee WS (2018) Molecular mechanisms underlying progesterone-induced cytoplasmic retention of p27 in breast cancer cells. J Steroid Biochem Mol Biol 183:202–209. https://doi.org/10.1016/j.jsbmb.2014.12.002 CrossRefPubMed

14.

Hsu SP, Lee WS (2011) Progesterone receptor activation of extranuclear signaling pathways in regulating p53 expression in vascular endothelial cells. Mol Endocrinol 25(3):421–432. https://doi.org/10.1210/me.2010-0424 CrossRefPubMedPubMedCentral

15.

Lin SY, Lee WR, Su YF, Lee WS (2012) Folic acid inhibits endothelial cell proliferation through activating the cSrc/ERK 2/NF-kB/p53 pathway mediated by folic acid receptor. Angiogenesis 15(4):671–683. https://doi.org/10.1007/s10456-012-9289-6 CrossRefPubMed

16.

Hou TC, Lin JJ, Wen HC, Chen LC, Hsu SP, Lee WS (2013) Folic acid inhibits endothelial cell migration through inhibiting the RhoA activity mediated by activating the folic acid receptor/c-SRC/p190RhoGAP-signaling pathway. Biochem Pharmacol 85(3):376–384. https://doi.org/10.1016/j.bcp.2012.11.011 CrossRefPubMed

17.

Lee TS, Lin JJ, Huo YN, Lee WS (2015) Progesterone inhibits endothelial cell migration through suppression of the rho activity mediated by cSrc activation. J Cell Biochem 116(7):1411–1418. https://doi.org/10.1002/jcb.25101 CrossRefPubMed

18.

Lee WS, Lu YC, Kuo CT, Chen CT, Tang PH (2018) Effects of female sex hormones on folic acid–induced anti-angiogenesis. Acta Physiol 222(4):e13001. https://doi.org/10.1111/apha.13001 CrossRef

19.

Wang HC, Lee WS (2014) Progesterone-induced migration inhibition in male rat aortic smooth muscle cells through the cSrc/AKT/ERK 2/p38 pathway-mediated up-regulation of p27. Endocrinology 155(4):1428–1435. https://doi.org/10.1210/en.2013-1838 CrossRefPubMed

20.

Wang HC, Hsu SP, Lee WS (2015) Extra-nuclear signaling pathway involved in progesterone-induced up-regulations of p21cip1 and p27kip1 in rat aortic smooth muscle cells. PLoS One 10(5):e0125903. https://doi.org/10.1371/journal.pone.0125903 CrossRefPubMedPubMedCentral

21.

Wang HC, Lee WS (2014) Progesterone induces RhoA inactivation in male rat aortic smooth muscle cells through up-regulation of p27kip1. Endocrinology 155(11):4473–4482. https://doi.org/10.1210/en.2014-1344 CrossRefPubMed

22.

Wen HC, Huo YN, Chou CM, Lee WS (2018) PMA inhibits endothelial cell migration through activating the PKC-δ/Syk/NF-κB-mediated upregulation of Thy-1. Sci Rep 8(1):16247. https://doi.org/10.1038/s41598-018-34548-8 CrossRefPubMedPubMedCentral

23.

Lee WS, Harder JA, Yoshizumi M, Lee ME, Haber E (1997) Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med 3(9):1005–1008. https://doi.org/10.1038/nm0997-1005 CrossRefPubMed

24.

Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM (1995) Folate levels and neural tube defects. Implications for prevention. JAMA 274(21):1698–1702. https://doi.org/10.1001/jama.1995.03530210052030 CrossRefPubMed

25.

Chong YP, Ia KK, Mulhern TD, Cheng HC (2005) Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases. Biochim Biophys Acta 1754(1–2):210–220. https://doi.org/10.1016/j.bbapap.2005.07.027 CrossRefPubMed

26.

Di Stefano P, Damiano L, Cabodi S, Aramu S, Tordella L, Parduroux A, Pica R, Cavallo F, Forni G, Silengo L, Tarone G, Turco E, Defilippi P (2007) p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. EMBO J 26(12):2843–2855. https://doi.org/10.1038/sj.emboj.7601724 CrossRefPubMedPubMedCentral

27.

Kuo CT, Lee WS (2016) Progesterone receptor activation is required for folic acid-induced anti-proliferation in colorectal cancer cell lines. Cancer Lett 378(2):104–110. https://doi.org/10.1016/j.canlet.2016.05.019 CrossRefPubMed

28.

Collett MS, Purchio AF, Erikson RL (1980) Avian sarcoma virus-transforming protein, pp60src shows protein kinase activity specific for tyrosine. Nature 285(5761):167–169. https://doi.org/10.1038/285167a0 CrossRefPubMed

29.

Hunter T, Sefton BM, Beemon K, Eckhart W (1980) Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus. Cell 20(3):807–816. https://doi.org/10.1016/0092-8674(80)90327-X CrossRefPubMed

30.

Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337–358. https://doi.org/10.1023/a:1023772912750 CrossRefPubMed

31.

Irby RB, Yeatman TJ (2000) Role of Src expression and activation in human cancer. Oncogene 19(49):5636–5642. https://doi.org/10.1038/sj.onc.1203912 CrossRefPubMed

32.

Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman TJ (1997) Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15(25):3083–3090. https://doi.org/10.1038/sj.onc.1201496 CrossRefPubMed

33.

Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, Nagai Y (1993) p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J 12(1):307–314. https://doi.org/10.1002/j.1460-2075.1993.tb05658.x CrossRefPubMedPubMedCentral

34.

Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21(2):187–190. https://doi.org/10.1038/5971 CrossRefPubMed

35.

Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T (2005) The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13(6):861–871. https://doi.org/10.1016/j.str.2005.03.012 CrossRefPubMed

36.

Xu Y, Singer MA, Lindquist S (1999) Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc Natl Acad Sci USA 96(1):109–114. https://doi.org/10.1073/pnas.96.1.109 CrossRefPubMed

37.

Okada M (2012) Regulation of the SRC family kinases by Csk. Int J Biol Sci 8:1385–1397. https://doi.org/10.7150/ijbs.5141 CrossRefPubMedPubMedCentral

38.

Somani AK, Bignon JS, Mills GB, Siminovitch KA, Branch DR (1997) Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase. J Biol Chem 272(34):21113–21119. https://doi.org/10.1074/jbc.272.34.21113 CrossRefPubMed

39.

Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP (2001) Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 8(2):269–280. https://doi.org/10.1016/S1097-2765(01)00304-5 CrossRefPubMed

40.

Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9(5):1603–1614. https://doi.org/10.1002/j.1460-2075.1990.tb08280.x CrossRefPubMedPubMedCentral

41.

Cheung J, Smith DF (2000) Molecular chaperone interactions with steroid receptors: an update. Mol Endocrinol 14(7):939–946. https://doi.org/10.1210/mend.14.7.0489 CrossRefPubMed

42.

Conneely OM, Mulac-Jericevic B, Lydon JP (2003) Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 68(10–13):771–778. https://doi.org/10.1016/S0039-128X(03)00126-0 CrossRefPubMed

43.

He B, Kemppainen JA, Wilson EM (2000) FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275(30):22986–22994. https://doi.org/10.1074/jbc.M002807200 CrossRefPubMed

44.

El-Ashry D, Onate SA, Nordeen SK, Edwards DP (1989) Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 3(10):1545–1558. https://doi.org/10.1210/mend-3-10-1545 CrossRefPubMed

45.

Gellersen B, Fernandes MS, Brosens JJ (2009) Non-genomic progesterone actions in female reproduction. Hum Reprod Update 15(1):119–138. https://doi.org/10.1093/humupd/dmn044 CrossRefPubMed

46.

Kay BK, Williamson MP, Sudol M (2000) The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J 14(2):231–241. https://doi.org/10.1096/fasebj.14.2.231 CrossRefPubMed

47.

Nada S, Okada M, MacAuley A, Cooper JA, Nakagawa H (1991) Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature 351(6321):69–72. https://doi.org/10.1038/351069a0 CrossRefPubMed

Title: Folic acid prevents the progesterone-promoted proliferation and migration in breast cancer cell lines
Authors: Hui-Chen Wang
Yen-Nien Huo
Wen-Sen Lee
Publication date: 01-09-2020
Publisher: Springer Berlin Heidelberg
Keywords: Folic Acid
Breast Cancer
Breast Cancer
Progesterone
Published in: European Journal of Nutrition / Issue 6/2020
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-019-02077-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2020

Effect of changes in adherence to Mediterranean diet on nutrient density after 1-year of follow-up: results from the PREDIMED-Plus Study

Metabolically and immunologically beneficial impact of extra virgin olive and flaxseed oils on composition of gut microbiota in mice

Berberis lycium fruit extract attenuates oxi-inflammatory stress and promotes mucosal healing by mitigating NF-κB/c-Jun/MAPKs signalling and augmenting splenic Treg proliferation in a murine model of dextran sulphate sodium-induced ulcerative colitis

Associations of sugar intake with anthropometrics in children from ages 2 until 8 years in the EU Childhood Obesity Project

Wheat-induced food allergy in childhood: ancient grains seem no way out

Soy isoflavones interact with calcium and contribute to blood pressure homeostasis in women: a randomized, double-blind, placebo controlled trial

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage